{"id":4333,"date":"2023-05-11T14:32:13","date_gmt":"2023-05-11T14:32:13","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?page_id=4333"},"modified":"2026-01-19T16:35:30","modified_gmt":"2026-01-19T16:35:30","slug":"pipeline","status":"publish","type":"page","link":"https:\/\/www.enyopharma.com\/fr\/science\/pipeline\/","title":{"rendered":"Pipeline"},"content":{"rendered":"<p>Â鶹Æƽâ°æ d\u00e9veloppe son portefeuille de produits avec la s\u00e9rie Vonafexor pour les maladies pr\u00e9sentant une insuffisance r\u00e9nale telles que le syndrome d&#8217;Alport, les maladies r\u00e9nales chroniques, la NASH et la n\u00e9phropathie diab\u00e9tique.<\/p>\n<p><a href=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2024\/01\/PipelineFR.png\"><img loading=\"lazy\" decoding=\"async\" src=\"https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2024\/01\/PipelineFR.png?resize=1024%2C300\" alt=\"\" width=\"1024\" height=\"300\" class=\"alignleft size-large wp-image-4523\" data-recalc-dims=\"1\" \/><\/a><\/p>\n<h2>Vonafexor (EYP001)<\/h2>\n<ul>\n<li><b>Molecule :<\/b> petite mol\u00e9cule ; agoniste synth\u00e9tique et non st\u00e9ro\u00efdien de FXR (r\u00e9cepteur farn\u00e9so\u00efde X ou r\u00e9cepteur des acides biliaires)<\/li>\n<li><b>Profil du m\u00e9dicament :<\/b> distribu\u00e9 principalement dans les reins et le foie<\/li>\n<li><b>Mode d&#8217;administration : <\/b>: oral (comprim\u00e9), une fois par jour<\/li>\n<li><b>Mode d&#8217;action:<\/b> fibrolytique and anti-inflammatoire<\/li>\n<li><b>D\u00e9veloppement clinique:<\/b> 11 \u00e9tudes cliniques r\u00e9alis\u00e9es : 7 Phases 1 et 4 Phases 2a<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>Â鶹Æƽâ°æ d\u00e9veloppe son portefeuille de produits avec la s\u00e9rie Vonafexor pour les maladies pr\u00e9sentant une insuffisance r\u00e9nale telles que le syndrome d\u2019Alport, les maladies r\u00e9nales chroniques, la NASH et la n\u00e9phropathie diab\u00e9tique.<\/p>\n","protected":false},"author":2,"featured_media":1014,"parent":4320,"menu_order":2,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-4333","page","type-page","status-publish","has-post-thumbnail","hentry"],"acf":[],"jetpack_sharing_enabled":true,"rttpg_featured_image_url":{"full":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=2000%2C750&ssl=1",2000,750,false],"landscape":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg",2000,750,false],"portraits":["https:\/\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg",2000,750,false],"thumbnail":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?resize=150%2C150&ssl=1",150,150,true],"medium":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=300%2C113&ssl=1",300,113,true],"large":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1024%2C384&ssl=1",1024,384,true],"1536x1536":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1536%2C576&ssl=1",1536,576,true],"2048x2048":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=2000%2C750&ssl=1",2000,750,true],"large_home":["https:\/\/i0.wp.com\/www.enyopharma.com\/wp-content\/uploads\/2016\/03\/pipeline.jpg?fit=1400%2C525&ssl=1",1400,525,true]},"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":null,"rttpg_excerpt":"Â鶹Æƽâ°æ d\u00e9veloppe son portefeuille de produits avec la s\u00e9rie Vonafexor pour les maladies pr\u00e9sentant une insuffisance r\u00e9nale telles que le syndrome d\u2019Alport, les maladies r\u00e9nales chroniques, la NASH et la n\u00e9phropathie diab\u00e9tique.","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4333","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4333"}],"version-history":[{"count":13,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4333\/revisions"}],"predecessor-version":[{"id":6368,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4333\/revisions\/6368"}],"up":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/pages\/4320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media\/1014"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4333"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}